Pear Therapeutics Closes Financing

Boston, MA (PRWEB) March 19, 2015 Pear Therapeutics, the creator of prescription pharmaceutical-software combination products called eFormulations™, announced today that it has successfully closed on additional financing. The funding round was led by 5AM Ventures, with several undisclosed additional investors contributing capital. The investment will allow Pear to build a portfolio of eFormulationsTM. Concurrently, Andrew […]

Vicus Therapeutics Announces Phase II Data Demonstrating Overall Survival Benefit with VT-122 Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma

MORRISTOWN, N.J (PRWEB) September 05, 2014 Vicus Therapeutics, an immuno-oncology company focused on bringing breakthrough immunotherapies to patients with solid-tumor cancers, announced positive results from a Phase II randomized, open-label, controlled clinical trial of its lead compound, VT-122, in combination with sorafenib, in patients with advanced hepatocellular carcinoma (HCC). In an intent-to-treat (ITT) population, investigators […]

Global Hospital Infection Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast- 2018

Albany, New York (PRWEB) July 20, 2014 Hospital acquired infections are the infections acquired by the patients following the admission in hospitals within 48 hours. These conditions are also known as nosocomial infections. The causative agents of nosocomial infections include various types of microorganisms such as bacteria (Gram-positive and Gram-negative), viruses and fungi. The most […]